Immunotherapy plus chemo shows promise against tough nasopharyngeal cancer
NCT ID NCT05201859
First seen May 08, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine works better than capecitabine alone for people with advanced nasopharyngeal carcinoma. The study includes 150 patients whose cancer did not fully respond to initial chemotherapy. After standard chemoradiotherapy, participants are randomly assigned to one of the two treatment groups. The main goal is to see if the combination improves the time patients live without their cancer returning or spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sintilimab (an immunotherapy drug) and capecitabine (a chemotherapy drug)
What this could lead to
If successful, this combination could improve the chance of keeping nasopharyngeal cancer from coming back after initial treatment.
What could go wrong
This is a mid-stage trial with only 150 participants, so results may not apply to everyone. Adding immunotherapy also raises the risk of immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.